SomaLogic and CM Life Sciences II S-4 Now Effective

CM Life Sciences II

The registration statement for the merger between CM Life Sciences II and SomaLogic has been declared effective by the SEC.

The SPAC plans to acquire the proteomics company for $651 million in cash.

Terms call for a fully committed PIPE of $375 million from both new and existing investors including Casdin Capital, Corvex Management, Janus Henderson Investors, SB Management, a subsidiary of SoftBank Group Corp, T.Rowe Price Associates, separate accounts advised by ARK Invest, Farallon Capital, Perceptive Advisors, funds and accounts managed by Counterpoint Global (Morgan Stanley), a new strategic investor Illumina, and an existing strategic investor, Novartis Pharma AG.

The combined company would have an enterprise value of $1.23 billion.

Pending shareholder approval, upon closing the combined company will list on the Nasdaq under SLGC. The deal is expected to close in the third quarter. Read more.

Total
0
Shares
Related Posts
Read More

M3-Brigade Acquisition IV Files for $200M IPO

Management in the S-1 filing said they expect to focus on businesses or companies with an enterprise value of at least $500 million, are based in North America and have been impacted positively or negatively by the COVID-19 pandemic or businesses in the renewable energy sector.